Christine Favre‐Guilmard

Author

Ipsen (France)

Also Known As

C. Favre-Guilmard, Christine Favre-Guilmard, Christine Favre‐Guilmard, Favre-Guilmard Christine

Publications

254

Citations

H-Index

Concepts

All Affiliations

Ipsen (France)Ipsen (United Kingdom)

About

Christine Favre‐Guilmard is an author at Ipsen (France) specializing in pain research, pain medicine, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	146
2	Health Sciences	1	1	15
3	Natural Sciences	1	1	12
4	Social Sciences	1	1	12
5	Allergy	1	1	115

Christine Favre‐Guilmard

Publications

245

Citations

H-Index

Page 1

	Year	Citations
Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models Christine Favre‐Guilmard, Michel Auguet, Pierre‐Etienne Chabrier European Journal of Pharmacology Pain SyndromeAllergyAcute PainPain MedicineMedicine	2009	115
Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models Mark Elliott, Christine Favre‐Guilmard, Sai Liu, Science Advances	2019	41
A comparison of biological activity of commercially available purified native botulinum neurotoxin serotypes A1 to F1 in vitro, ex vivo, and in vivo Sarah Donald, Mark Elliott, Bryony Gray, Pharmacology Research & Perspectives	2018	27
Recombinant botulinum neurotoxin serotype A1 in vivo characterization Cindy Périer, Vincent Martin, Sylvie Cornet, Pharmacology Research & Perspectives	2021	19
The novel inhibitor of the heterotrimeric G-protein complex, BIM-46187, elicits anti-hyperalgesic properties and synergizes with morphine Christine Favre‐Guilmard, Hamida Zeroual-Hider, C. Soulard, European Journal of Pharmacology Novel InhibitorBiochemistryFunctional SelectivityPain MedicineMedicine	2008	16
Butyl 2-(4-[1.1′-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate, a potent sodium channel blocker for the treatment of neuropathic pain Anne‐Marie Liberatore, Jocelyne Schulz, Christine Favre‐Guilmard, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicinal ChemistryPain DisordersHealth SciencesPain Medicine	2006	15
Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems Mark Elliott, Jacquie Maignel, Sai Liu, PLoS ONE ToxinologyMolecular BiologySocial SciencesBotulinum NeurotoxinsNeuroimmunology	2017	12

Page 1